Effect of the antitumoral alkylating agent 3-bromopyruvate on mitochondrial respiration: role of mitochondrially bound hexokinase.
The alkylating agent 3-Bromopyruvate (3-BrPA) has been used as an anti-tumoral drug due to its anti-proliferative property in hepatomas cells. This propriety is believed to disturb glycolysis and respiration, which leads to a decreased rate of ATP synthesis. In this study, we evaluated the effects of the alkylating agent 3-BrPA on the respiratory states and the metabolic steps of the mitochondria of mice liver, brain and in human hepatocarcinoma cell line HepG2. The mitochondrial membrane potential (ΔΨ(m)), O(2) consumption and dehydrogenase activities were rapidly dissipated/or inhibited by 3-BrPA in respiration medium containing ADP and succinate as respiratory substrate. 3-BrPA inhibition was reverted by reduced glutathione (GSH). Respiration induced by yeast soluble hexokinase (HK) was rapidly inhibited by 3-BrPA. Similar results were observed using mice brain mitochondria that present HK naturally bound to the outer mitochondrial membrane. When the adenine nucleotide transporter (ANT) was blocked by the carboxyatractiloside, the 3-BrPA effect was significantly delayed. In permeabilized human hepatoma HepG2 cells that present HK type II bound to mitochondria (mt-HK II), the inhibiting effect occurred faster when the endogenous HK activity was activated by 2-deoxyglucose (2-DOG). Inhibition of mt-HK II by glucose-6-phosphate retards the mitochondria to react with 3-BrPA. The HK activities recovered in HepG2 cells treated or not with 3-BrPA were practically the same. These results suggest that mitochondrially bound HK supporting the ADP/ATP exchange activity levels facilitates the 3-BrPA inhibition reaction in tumors mitochondria by a proton motive force-dependent dynamic equilibrium between sensitive and less sensitive SDH in the electron transport system.
Laboratório de Bioenergética e Fisiologia Mitocondrial, Programa de Bioquímica e Biofísica Celular, Instituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho 373 - CCS, Bl. D, ss13, Rio de Janeiro, 21941-902 RJ, Brazil.
Clara
C
Rodrigues-Ferreira
Ana Paula Pereira
AP
da Silva
Antonio
A
Galina
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D001921:Brain / Q000378:metabolism; D019069:Cell Respiration / Q000187:drug effects*; D003847:Deoxyglucose; D019298:Glucose-6-Phosphate; D056945:Hep G2 Cells; D006593:Hexokinase / Q000378:metabolism*; D006801:Humans; D008099:Liver / Q000378:metabolism; D008297:Male; D053078:Membrane Potential, Mitochondrial; D051379:Mice; D008928:Mitochondria / Q000187:drug effects* / Q000201:enzymology; D010101:Oxygen Consumption; D011773:Pyruvates / Q000494:pharmacology*; D013050:Spectrometry, Fluorescence; D013385:Succinate Dehydrogenase / Q000378:metabolism
D018906:Antineoplastic Agents, Alkylating; D011773:Pyruvates; D019298:Glucose-6-Phosphate; C017092:bromopyruvate; D003847:Deoxyglucose; D013385:Succinate Dehydrogenase; D006593:Hexokinase